The calpain-suppressing effects of olesoxime in Huntington's disease

References

• Bordet T, Buisson B, Michaud M, Drouot C, Galéa P, Delaage P, Akentieva NP, Evers AS, Covey DF, Ostuni M A, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther [Internet] 2007; 322:709-20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17496168; PMID:17496168; http://dx.doi.org/10.1124/jpet.107.123000
   Google Scholar
• Bordet T, Berna P, Abitbol JL, Pruss RM. Olesoxime (TRO19622): A novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals 2010; 3:345-68; http://dx.doi.org/10.3390/ph3020345
   Google Scholar
• Colombini M. VDAC: the channel at the interface between mitochondria and the cytosol. Mol Cell Biochem 256-257:107-15; PMID:14977174
   Google Scholar
• Gatliff J, Campanella M. The 18 kDa translocator protein (TSPO): a new perspective in mitochondrial biology. Curr Mol Med 2012; 12:356-68; PMID:22364127
   Google Scholar
• Veenman L, Shandalov Y, Gavish M. VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis. J Bioenerg Biomembr 2008; 40:199-205; PMID: 18670869; http://dx.doi.org/10.1007/s10863-008-9142-1
   Google Scholar
• Gouarné C, Tracz J, Paoli MG, Deluca V, Seimandi M, Tardif G, Xilouri M, Stefanis L, Bordet T, Pruss RM. Protective role of olesoxime against wild-type α-synuclein-induced toxicity in human neuronally differentiated SHSY-5Y cells. Br J Pharmacol [Internet] 2015; 172:235-45. Available from: http://doi.wiley.com/10.1111/bph.12939; PMID: 25220617; http://dx.doi.org/10.1111/bph.12939
   Google Scholar
• Gouarné C, Giraudon-Paoli M, Seimandi M, Biscarrat C, Tardif G, Pruss RM, Bordet T. Olesoxime protects embryonic cortical neurons from camptothecin intoxication by a mechanism distinct from BDNF. Br J Pharmacol 2013; 168:1975-88; PMID:23278424; http://dx.doi.org/10.1111/bph.12094
   Google Scholar
• Rovini A, Carré M, Bordet T, Pruss RM, Braguer D. Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. Biochem Pharmacol 2010; 80:884-94; PMID:20417191; http://dx.doi.org/10.1016/j.bcp.2010.04.018
   Google Scholar
• Magalon K, Zimmer C, Cayre M, Khaldi J, Bourbon C, Robles I, Tardif G, Viola A, Pruss RM, Bordet T, et al. Olesoxime accelerates myelination and promotes repair in models of demyelination. Ann Neurol 2012; 71:213-26; PMID:22367994; http://dx.doi.org/10.1002/ana.22593
   Google Scholar
• Sunyach C, Michaud M, Arnoux T, Bernard-Marissal N, Aebischer J, Latyszenok V, Gouarné C, Raoul C, Pruss RM, Bordet T, et al. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology 2012; 62:2346-52; PMID:22369784; http://dx.doi.org/10.1016/j.neuropharm.2012.02.013
   Google Scholar
• Richter F, Gao F, Medvedeva V, Lee P, Bove N, Fleming SM, Michaud M, Lemesre V, Patassini S, De La Rosa K, et al. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons. Neurobiol Dis 2014; 69:263-75; PMID:24844147; http://dx.doi.org/10.1016/j.nbd.2014.05.012
   Google Scholar
• Bordet T, Buisson B, Michaud M, Abitbol J-L, Marchand F, Grist J, Andriambeloson E, Malcangio M, Pruss RM. Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. J Pharmacol Exp Ther 2008; 326:623-32; PMID:18492948; http://dx.doi.org/10.1124/jpet.108.139410
   Google Scholar
• Xiao WH, Zheng FY, Bennett GJ, Bordet T, Pruss RM. Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain 2009; 147:202-9; PMID:19833436; http://dx.doi.org/10.1016/j.pain.2009.09.006
   Google Scholar
• Xiao WH, Zheng H, Bennett GJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 2012; 203:194-206; PMID:22200546; http://dx.doi.org/10.1016/j.neuroscience.2011.12.023
   Google Scholar
• Lenglet T, Lacomblez L, Abitbol JL, Ludolph a., Mora JS, Robberecht W, Shaw PJ, Pruss RM, Cuvier V, Meininger V. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol 2014; 21:529-36; PMID:24447620; http://dx.doi.org/10.1111/ene.12344
   Google Scholar
• Dessaud E, Carole A, Bruno S, Patrick B, Rebecca P, Cuvier V, Hauke W, Enrico B, Mcdonald C, Watson C, et al. A Phase II study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year-old Spinal Muscular Atrophy (SMA) patients. Neurol Emerg Abstr 2014; 83:e34-40
   Google Scholar
• Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 2005; 25:9932-9; PMID:16251441; http://dx.doi.org/10.1523/JNEUROSCI.3355-05.2005
   Google Scholar
• Browne SE. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann N Y Acad Sci 2008; 1147:358-82; PMID:19076457; http://dx.doi.org/10.1196/annals.1427.018
   Google Scholar
• Clemens LE, Weber JJ, Wlodkowski TT, Yu-Taeger L, Michaud M, Calaminus C, Eckert SH, Gaca J, Weiss A, Magg JCD, et al. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. Brain 2015; 138:3632-53; http://dx.doi.org/10.1093/brain/awv290
   Google Scholar
• Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, Li SH, Yi H, Vonsattel JP, Gusella JF, et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 2000; 9:503-13; PMID:10699173; http://dx.doi.org/10.1093/hmg/9.4.503
   Google Scholar
• Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp a H, Persichetti F, Cattaneo E, MacDonald ME. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 2000; 9:2799-809; PMID:11092756; http://dx.doi.org/10.1093/hmg/9.19.2799
   Google Scholar
• Eckmann J, Clemens LE, Eckert SH, Hagl S, Yu-Taeger L, Bordet T, Pruss RM, Muller WE, Leuner K, Nguyen HP, et al. Mitochondrial membrane fluidity is consistently increased in different models of huntington disease: restorative effects of olesoxime. Mol Neurobiol 2014; 50:107-18; PMID:24633813
   Google Scholar
• Menalled LB. Knock-in mouse models of Huntington's disease. NeuroRx 2005; 2:465-70; PMID:16389309; http://dx.doi.org/10.1602/neurorx.2.3.465
   Google Scholar
• Brustovetsky N, LaFrance R, Purl KJ, Brustovetsky T, Keene CD, Low WC, Dubinsky JM. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease. J Neurochem 2005; 93:1361-70; PMID:15935052; http://dx.doi.org/10.1111/j.1471-4159.2005.03036.x
   Google Scholar
• Yu-Taeger L, Petrasch-Parwez E, Osmand AP, Redensek A, Metzger S, Clemens LE, Park L, Howland D, Calaminus C, Gu X, et al. A novel BACHD transgenic rat exhibits characteristic neuropathological features of huntington disease. J Neurosci 2012; 32:15426-38; PMID:23115180; http://dx.doi.org/10.1523/JNEUROSCI.1148-12.2012
   Google Scholar
• Jansson EKH, Clemens LE, Riess O, Nguyen HP. Reduced motivation in the BACHD rat model of huntington disease is dependent on the choice of food deprivation strategy. PLoS One 2014; 9:e105662; PMID:25144554; http://dx.doi.org/10.1371/journal.pone.0105662
   Google Scholar
• Abràmoff MD, Magalhães PJ, Sunanda J. Image processing with ImageJ. Biophotonics Int 2004; 11:36-42.
   Google Scholar